Ronapreve for prophylaxis and treatment of covid-19

Sidebottom, David B.

doi:10.1136/bmj.n2136

Cited by 13 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In asymptomatic individuals with an initial positive PCR result, treatment with casirivimab/imdevimab reduced the development of symptomatic disease by 31% ( p < 0.038) [ 24 ]. However, the cost and limited supply of casirivimab/imdevimab emphasizes the need to ensure it is allocated to those that stand to gain the most benefit: seronegative SARS-CoV-2 patients after three injections of the vaccine and receiving belatacept could be good candidates [ 25 ].…”

Section: Covid-19 and Belataceptmentioning

confidence: 99%

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response

Terrec

Jouve

Malvezzi

et al. 2021

JCM

View full text Add to dashboard Cite

Introduction: Belatacept is a common immunosuppressive therapy used after kidney transplantation (KT) to avoid calcineurin-inhibitor (CNI) use and its related toxicities. It is unclear whether its use exposes KT recipients (KTx) to a greater risk of infection or a poorer response to vaccines. Areas covered: We reviewed PubMed and the Cochrane database. We then summarized the mechanisms and impacts of belatacept use on the risk of infection, particularly opportunistic, in two settings, i.e., de novo KTx and conversion from CNIs. We also focused on COVID-19 infection risk and response to SARS-CoV-2 vaccination in patients whose maintenance immunosuppression relies on belatacept. Expert opinion: When belatacept is used de novo, or after drug conversion the safety profile regarding the risk of infection remains good. However, there is an increased risk of opportunistic infections, mainly CMV disease and Pneumocystis pneumonia, particularly in those with a low eGFR, in older people, in those receiving steroid-based therapy, or those that have an early conversion from CNI to belatacept (i.e., <six months post-transplantation). Thus, we recommend, if possible, delaying conversion from CNI to belatacept until at least six months post-transplantation. Optimal timing seems to be eight months post-transplantation. In addition, KTx receiving belatacept respond poorly to SARS-CoV-2 vaccination.

show abstract

Section: Covid-19 and Belataceptmentioning

confidence: 99%

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response

Terrec

Jouve

Malvezzi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Ronapreve, cocktail of casirivimab and imdevimab ) ( Beigel et al. 2020 ; Sidebottom and Gill 2021 ). The UpSet plot in the Ronapreve tab allows users to track amino acid substitutions known to affect either casirivimab or imdevimab mAbs and in combination ( Fig.…”

Section: Discussionmentioning

confidence: 99%

Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer

et al. 2022

View full text Add to dashboard Cite

COG-UK Mutation Explorer (COG-UK-ME, https://sars2.cvr.gla.ac.uk/cog-uk/ - Last Accessed date 16/03/22) is a web resource that displays knowledge and analyses on SARS-CoV-2 virus genome mutations and variants circulating in the UK, with a focus on the observed amino acid replacements that have an antigenic role in the context of the human humoral and cellular immune response. This analysis is based on more than 2 million genome sequences (as of March 2022) for UK SARS-CoV-2 data held in the CLIMB-COVID centralised data environment. COG-UK-ME curates these data and displays analyses that are cross-referenced to experimental data collated from the primary literature. The aim is to track mutations of immunological importance that are accumulating in current variants of concern and variants of interest that could alter the neutralising activity of monoclonal antibodies (mAbs), convalescent sera and vaccines. Changes in epitopes recognised by T cells, including those where reduced T cell binding has been demonstrated, are reported. Mutations that have been shown to confer SARS-CoV-2 resistance to antiviral drugs are also included. Using visualisation tools, COG-UK-ME also allows users to identify the emergence of variants carrying mutations that could decrease the neutralising activity of both mAbs present in therapeutic cocktails, e.g., Ronapreve. COG-UK-ME tracks changes in frequency of combination of mutations and brings together curated literature on the impact of those mutations on various functional aspects of the virus and therapeutics. Given SARS-CoV-2 unpredictable nature as exemplified by yet another variant of concern, Omicron, continued surveillance of SARS-CoV-2 remains imperative to monitor virus evolution linked to the efficacy of therapeutics.

show abstract

“…Adverse effects are also important, and maoto has been shown to have few. Many prophylactic and therapeutic drugs have been proposed for use against COVID-19 [ 12 ], such as hydroxychloroquine, ivermectin, and monoclonal antibodies (casirivimab and imdevimab) [ 33 ]. Other traditional herbal medicines became candidates for the treatment of COVID-19 [ 29 ].…”

Section: Discussionmentioning

confidence: 99%